NxStage posts record-breaking Q3 results, shares gain 13%
November 8, 2012 by MassDevice staff
NxStage boasts another solid quarter with a nearly double-digit increase in sales and halved 3rd quarter losses, gaining a 13% boost on Wall Street.
NxStage Medical (NSDQ:NXTM) posted yet another record-breaking quarter, cutting losses in half and reporting strong growth in sales.
- Show full page
- Login to post comments
-
Permalink
RECENT BLOG POSTS
- Mobilizing on the back end of a disaster
- Rising healthcare costs not directly tied to medical technology, according to study
- CareFusion may be weighing 2 very different deals
- Medical Devices: What does it really mean to be disruptive?
- Smarter strategic moves bode well for Wright Medical
- The IRS, NSA, and Justice Department scandals and what they mean for HIPAA
- A Father's Day remembrance
- What I'd tell the graduating medical school class of 2013
- Silencing immune attacks in type 1 diabetes
- Eucomed guidance clarifies RoHS compliance for medical device companies
Navigation
NEWS
Edwards Lifesciences' Perimount heart valve fares well in 25-year study
A clinical study tracking Edwards Lifesciences' Perimount heart valve over a 25-year span finds that...
St. Jude's Durata defibrillator 'immune' to Riata flaws?
St. Jude Medical's Durata implantable cardiac defibrillator leads should be "relatively immune...
Weight loss: GI Dynamics adds centers in Europe
GI Dynamics says another 5 centers in Europe are offering its EndoBarrier weight-loss device for...
Boston Scientific launches U.S. Parkinson's trial, cites interim EU data
Boston Scientific launches a U.S. clinical trial of its Vercise deep-brain stimulation treatment for...
